A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis

References

• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
   PubMed Web of Science ®Google Scholar
• Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol 2008; 295: H2399–H2408.
   Web of Science ®Google Scholar
• Song C, Shen Y, Yamen E et al. Serum amyloid A may potentiate prothrombotic and pro-inflammatory events in acute coronary syndromes. Atherosclerosis 2009; 202: 596–604.
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–424.
   PubMed Web of Science ®Google Scholar
• Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355–1361.
   PubMed Web of Science ®Google Scholar
• Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA 1994; 91: 3186–3190.
   PubMed Web of Science ®Google Scholar
• Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
   Google Scholar
• Heitzer T, Schlinzig T, Krohn K, Meinertz T, Miinzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–2678.
   PubMed Web of Science ®Google Scholar
• Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes Jr DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–954.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Drummond G, Witting PK. Redox signaling in endothelial function and dysfunction: molecular mechanisms and therapeutic options. Antiox Redox Signaling 2008; 10: 1714–1745.
   Google Scholar
• Manzel T, Daiber A, Ullrich V, Millsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase Arterioscler Thromb Vasc Biol 2005; 25: 1551-1557.
   Google Scholar
• Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH. Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol 1997; 10: 1285–1292.
   PubMed Web of Science ®Google Scholar
• Witting PK, Rayner BS, Wu BJ, Ellis NA, Stocker R. Hydrogen peroxide promotes vascular dysfunction through decreasing nitric oxide bioavailability. Cell Physiol Biochem 2007; 20: 255–268.
   PubMed Web of Science ®Google Scholar
• Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817–826.
   PubMed Web of Science ®Google Scholar
• Steel DM, Sellar GC, Uhlar CM, Simon S, DeBeer FC, Whitehead AS. A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with an acute-phase serum amyloid A protein gene (SAA2). Genomics 1993; 16: 447–454.
   PubMed Web of Science ®Google Scholar
• Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998; 334: 489–503.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–454.
   PubMed Web of Science ®Google Scholar
• Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 1994; 27: 469–473.
   PubMed Web of Science ®Google Scholar
• Hilliquin P. Biological markers in inflammatory rheumatic diseases. Cell Mol Biol 1995; 41: 993–1006.
   PubMed Web of Science ®Google Scholar
• Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986; 39: 794–797.
   PubMed Web of Science ®Google Scholar
• Fyfe AT, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96: 2914–2919.
   PubMed Web of Science ®Google Scholar
• Larson MA, Wei SH, Weber A, Weber AT, McDonald TL. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun 2003; 301: 1030–1037.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Klein J, Kralisch Set al. Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J Endocrinol 2004; 183: 561–567.
   PubMed Web of Science ®Google Scholar
• de Beer MC, Yuan T, Kindy MS, Asztalos BF, Roheim PS, DeBeer FC. Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J Lipid Res 1995; 36: 526–534.
   PubMed Web of Science ®Google Scholar
• Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues: predominant localization to the epithelium. J Histochem Cytochem 1998; 46: 1377–1384.
   PubMed Web of Science ®Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501–523.
   PubMedGoogle Scholar
• Urieli-Shoval S, Linke RP, Matzner Y Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000; 7: 64–69.
   PubMed Web of Science ®Google Scholar
• Bausserman LL, Van Saritelli AL, Zuiden P, Gollaher CJ, Herbert PN. Degradation of serum amyloid A by isolated perfused rat liver. J Biol Chem 1987; 262: 1583–1589.
   PubMed Web of Science ®Google Scholar
• Raynes JG, Cooper EH. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol1983; 36: 798-803.
   Google Scholar
• Tape C, Kisilevsky R. Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1990; 1043: 295–300.
   PubMed Web of Science ®Google Scholar
• Gollaher CJ, Bausserman LL. Hepatic catabolism of serum amyloid A during an acute phase response and chronic inflammation. Proc Soc Exp Biol Med 1990; 194: 245–250.
   PubMed Web of Science ®Google Scholar
• Poitou C, Viguerie N, Cancello R et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005; 48: 519–528.
   PubMed Web of Science ®Google Scholar
• O'Hara R, Murphy EP, Whitehead AS, Fitzgerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis
   Google Scholar
• He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G-protein-coupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572–1581.
   PubMed Web of Science ®Google Scholar
• Baranova IN, Vishnyakova TG, Bocharov AV et al. Serum amyloid
   Google Scholar
• Cai H, Song C, Endoh I et al. Serum amyloid A induces monocyte
   Google Scholar
• He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like
   Google Scholar
• Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol.
   Google Scholar
• Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate
   Google Scholar
• Badolato R, Wang JM, Stornello SL, Ponzi AN, Duse M, Musso T. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti.
   Google Scholar
• Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, DeBeer FC. Serum amyloid A-containing human high
   Google Scholar
• Van Lenten BJ, Hama SY, DeBeer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response.
   Google Scholar
• Gotto AMJ, Brinton EA. Assessing low levels of high-density
   Google Scholar
• Nobécourt E, Jacqueminet S, Hansel B et al. Defective antioxidative
   Google Scholar
• Gown i MS, van der Westhuyzen DR, Bridges SR, Anderson JW.
   Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med
   Google Scholar
• Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol 2008; 28: 1890–1891.
   PubMed Web of Science ®Google Scholar
• Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized low-
   Google Scholar
• Matsunaga T, Iguchi K, Nakajima T et al. Glycated high-density lipoprotein induces apoptosis of endothelial cells via
   Google Scholar
• Perségol L, Verges B, Foissac M, Gambert P, Duvillard L. Inability
   Google Scholar
• Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diabetes Rep 2008; 8: 51–59.
   PubMed Web of Science ®Google Scholar
• Pussinen PJ, Metso J, Keva R et al. Plasma phospholipid transfer modification of high density lipoprotein. Int J Biochem Cell Biol 2003; 35: 192–202.
   PubMed Web of Science ®Google Scholar
• Karabina SA, Lehner AN, Frank E, Parthasarathy S, Santanam N. Oxidative inactivation of paraoxonase - implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 2005; 1725: 213–221.
   PubMed Web of Science ®Google Scholar
• Heinecke JW. The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007; 9: 249–251.
   PubMedGoogle Scholar
• Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006; 21: 322–328.
   PubMed Web of Science ®Google Scholar
• Eriksen N, Benditt EP. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci USA 1980; 77: 6860–6864.
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22: 933–940.
   PubMed Web of Science ®Google Scholar
• Banka CL, Yuan T, de Beer MC, Kindy MS, Curtiss LK, DeBeer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995; 36: 1058–1065.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
   PubMed Web of Science ®Google Scholar
• O'Brien K, Chait A. Serum amyloid A: the ‘other’ inflammatory protein. Curr Atheroscler Rep 2006; 8: 62–68.
   PubMedGoogle Scholar
• van Eijk IC, de Vries MK, Levels JH et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324–1330.
   PubMed Web of Science ®Google Scholar
• Bausserman LL, Herbert PN, Rodger R, Nicolosi RJ. Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim Biophys Acta 1984; 792: 186–191.
   PubMed Web of Science ®Google Scholar
• Liang JS, Schreiber BM, Salmona M et al. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 1996; 37: 2109–2116.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989; 1006: 173–178.
   PubMed Web of Science ®Google Scholar
• Pruzanski W, Stefanski E, DeBeer FC et al. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. J Lipid Res 1998; 39: 2150–2160.
   PubMed Web of Science ®Google Scholar
• Lindhorst E, Young D, Bagshaw W, Hyland M, Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997; 1339: 143–154.
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155–161.
   PubMed Web of Science ®Google Scholar
• Lee HY, Kim SD, Shim JW et al. Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 2008; 181: 4332.
   PubMed Web of Science ®Google Scholar
• Kumon Y, Hosokawa T, Suehiro T, Ikeda Y, Sipe JD, Hashimoto K. Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid 2002; 9: 237–241.
   PubMed Web of Science ®Google Scholar
• Badolato R, Wang JM, Murphy WJ et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180: 203–209.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhou S, Heng CK. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler Thromb Vase Biol 2007; 27: 1645-1650. Song CJ, Nakagomi A, Chandar S et al. C-reactive protein contributes to the hypercoagulable state in coronary artery disease. J Thromb Haemost 2006; 4: 98–106.
   PubMedGoogle Scholar
• Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722–731.
   PubMed Web of Science ®Google Scholar
• Mezaki T, Matsubara T, Hon i T et al. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 2003; 44: 601–612.
   PubMedGoogle Scholar
• Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A,
   Google Scholar
• Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387–394.
   PubMed Web of Science ®Google Scholar
• Wong M, Toh L, Wilson A et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48: 81–89.
   PubMed Web of Science ®Google Scholar
• Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355–2363.
   PubMed Web of Science ®Google Scholar
• Vallon R, Freuler F, Desta-Tsedu N et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166: 2801–2807.
   PubMed Web of Science ®Google Scholar
• Lewis KE, Kirk EA, McDonald TO et al. Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004; 110: 540–545.
   PubMed Web of Science ®Google Scholar
• O'Brien KD, McDonald TO, Kunjathoor V et al. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 785–790.
   PubMed Web of Science ®Google Scholar
• Hayat S, Raynes JG. Acute phase serum amyloid A protein increases high density lipoprotein binding to human peripheral blood mononuclear cells and an endothelial cell line. Scand J Immunol 2000; 51: 141–146.
   PubMed Web of Science ®Google Scholar
• Wilson PG, Thompson JC, Webb NR, DeBeer FC, King VL, Tannock LR. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 2008; 173: 1902–1910.
   PubMed Web of Science ®Google Scholar
• Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol 1999; 26: 785–790.
   PubMed Web of Science ®Google Scholar
• Ashby D, Gamble J, Vadas Met al. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis 2001; 154: 113–121.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A2.1. J Lipid Res 2003; 44: 2257–2269.
   PubMed Web of Science ®Google Scholar
• Tam SP, Ancsin JB, Tan R, Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-i-mice. J Lipid Res 2005; 46: 2091–2101.
   PubMed Web of Science ®Google Scholar